Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of RZ358 in Congenital Hyperinsulinism
2023-503240-13-00Phase 3Authorised
- Sponsor
- Rezolute, Inc.
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in congenital hyperinsulinism (HI) comparing RZ358 with Placebo (2 arms). Primary endpoint: Change in average weekly incidence of hypoglycemia events by SMBG after 24 weeks. Planned start Dec 2023; status: authorised.
02
Drugs
ersodetug
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on 2023-503240-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503240-13-00.